In Utero Exposure to Dolutegravir-Based Antiretroviral Therapy Alters Growth and Metabolic Outcomes

Clicks: 10
ID: 327285
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #139 of 147 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 147 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Background Approximately 5,000 women living with HIV give birth each year, with perinatal transmission occurring in less than 1% of cases. The World Health Organization (WHO) recommends dolutegravir (DTG) as first and second line antiretroviral therapy (ART), readily crossing the placenta, resulting in persistent exposure throughout development. In adults, DTG-based ART has been linked to metabolic changes, including alterations in bone mineral density and body composition. The effects of DTG exposure on bone development and body composition trajectories in HIV-exposed uninfected (HEU) children are currently unknown. Methods Female C57BL/6J mice (8–10 weeks old) were mated with 3–4-month-old males. Dams were assigned to either dolutegravir/tenofovir disoproxil fumarate/lamivudine (DTG/TDF/3TC) infused pellets (ART) or control pellets from mating until weaning at postnatal day (PND) 28. Offspring body weights were recorded from PND15 to 86. Body composition was assessed using DEXA at PND36 and PND50. At PND28, circulating leptin and adiponectin were measured, and visceral adipose tissue gene expression (leptin and PPARγ) was assessed by qPCR. Results Maternal exposure to DTG-based ART was associated with increased body weight in both sexes, with larger differences in males (PND36: Males 20.28 ± 0.6 g vs 19.16 ± 0.5 g, p = 0.03; Females 17.15 ± 0.4 g vs 16.41 ± 0.3 g, p = 0.05). DEXA analysis demonstrated higher lean mass (PND50: Males 11.5 ± 0.4 cm2 vs 11.0 ± 0.3 cm2, p = 0.04; Females 10.8 ± 0.3 cm2 vs 10.4 ± 0.2 cm2, p = 0.08) and increased fat area (PND50: Males 4.0 ± 0.2 cm2 vs 3.5 ± 0.2 cm2, p = 0.02; Females 3.3 ± 0.1 cm2 vs 3.0 ± 0.1 cm2, p = 0.07) in ART-exposed pups compared to controls. Bone mineral content was elevated in ART-exposed offspring at PND36 and PND50 (PND50: Males 0.55 ± 0.02 g vs 0.48 ± 0.02 g, p = 0.01; Females 0.50 ± 0.01 g vs 0.44 ± 0.01 g, p = 0.02). Serum adiponectin showed a significant increase in ART-treated males (p = 0.02), with a trend toward increased circulating leptin in both treated sex groups. Visceral adipose tissue showed greater adipocyte differentiation in control pups, supported by elevated leptin and PPARγ expression. Conclusion Perinatal exposure to DTG/TDF/3TC during pregnancy and breastfeeding alters growth, body composition and adipose transcriptional profiles in offspring. This suggests maternal ART may shape early-life metabolic programming, highlighting the importance of monitoring outcomes in HEU children.
Reference Key
openalex_W7204632536 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag070/piag070.016
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.